Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Murnia

Financiado

Prevention of Radiotherapy and Chemotherapy Induced Oromucosal Wounds Using an O...

Prevention of Radiotherapy and Chemotherapy Induced Oromucosal Wounds Using an Oral Application Gel: Murnia® Mouth Gel Cancer is a devastating and costly condition expected to increase significantly by 2030. According to the 2018 WHO report, the global cancer burden is estimated at 18.1 million new cases annually . Mucositis is a condition in canc... ver más

30/06/2024

UMAYANA ARASTIRMA...

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

UMAYANA ARASTIRMA GELISTIRME VE ILAC SANAYI A... No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU

Innovación

Cerrada hace 2 años

0% 100% 100%

1 Participantes

UMAYANA ARASTIRMA GELISTIRME...

75.00K€ | Lider

Proyectos interesantes

PID2021-128412OB-I00 PLATAFORMAS MULTIMODALES PARA LA REGENERACION DE LA MUCOSA O... 190K€ Cerrado

SAF2013-49019-P UN GEL DE MELATONINA QUE PREVIENE Y CURA LA MUCOSITIS: EVALU... 109K€ Cerrado

SAF2008-05355 PAPEL DEL EGF EN LA REGENERACION DE LA MUCOSA DEL COLON DURA... 73K€ Cerrado

ReSinAge Regeneration of Sinusoidal niches to preserve hematopoiesis... 2M€ Cerrado

SAF2009-14037 BASES MOLECULARES Y CELULARES DE LA MUCOSITIS INDUCIDA POR R... 85K€ Cerrado

PID2019-108958RB-I00 HIDROGELES DE MATRIZ EXTRACELULAR PULMONAR PARA PREACONDICIO... 169K€ Cerrado

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 12 meses Fecha Inicio: 2023-06-07
Fecha Fin: 2024-06-30

Presupuesto del proyecto 75K€

Descripción del proyecto Cancer is a devastating and costly condition expected to increase significantly by 2030. According to the 2018 WHO report, the global cancer burden is estimated at 18.1 million new cases annually . Mucositis is a condition in cancer patients that manifests as severe ulcerations in the mouth and the gastrointestinal tract. Oral mucositis (OM) is cancer treatment's most significant side effect worldwide . Mucositis can be caused by chemotherapy and/or radiotherapy. It occurs in nearly 40% of patients receiving conventional CT, 80% receiving high-dose CT as conditioning for haematopoietic stem cell transplantation, and 100% receiving H&N radiation therapy, with 65% of those progressing to severe grade levels with significant adverse outcomes. The problem with OM is that while current therapies are focussed on dealing with its symptoms like inability to eat or significant pain, there is no real cure or prevention for OM itself. Existing products in the market for OM mainly offer symptom management focusing on pain or, at best, duration reduction claims. The one approved drug for chemotherapy and radiotherapy, Amifostine, has severe side effects and tumour protective properties, making it hard to use as it interferes with the actual cancer treatment. Kepivance, which is only approved for haematological malignancies, is challenging to administer, posing compliance issues and does not solve the more significant need for solid tumours. Umayana has developed a proprietary preventative and curative formulation to combat OM in cancer patients. Global Patent: WO2020072987 USA Patent: 11331360 (B2).

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores